Efficacy of Oncolytic Adenovirus Expressing Suicide Genes and Interleukin-12 in Preclinical Model of Prostate Cancer

Overview

Journal Gene Ther

Date 2013 Jul 12

PMID 23842593

Citations 37

Authors

S O Freytag

K N Barton

Y Zhang

Affiliations

Soon will be listed here.

Abstract

Oncolytic adenovirus-mediated suicide gene therapy has been shown to improve local tumor control in preclinical tumor models and in the clinic. Although local tumor control is important, for most human cancers, new therapies must also target metastatic disease if they are to have an impact on survival. Here, we test the hypothesis that adding cytokine gene therapy to our multimodal platform improves both local and metastatic tumor control in a preclinical model of prostate cancer. An oncolytic adenovirus (Ad5-yCD/mutTKSR39rep-mIL12) expressing two suicide genes and mouse interleukin-12 (IL-12) was generated. Relative to an adenovirus lacking IL-12 (Ad5-yCD/mutTKSR39rep), Ad5-yCD/mutTKSR39rep-mIL12 improved local and metastatic tumor control in the TRAMP-C2 prostate adenocarcinoma model, resulting in a significant increase in survival. Ad5-yCD/mutTKSR39rep-mIL12 resulted in high levels of IL-12 and interferon gamma in serum and tumor, increased natural killer (NK) and cytotoxic T-lymphocyte lytic activities, and the development of tumor-specific antitumor immunity. Immune cell depletion studies indicated that both the innate and adaptive arms of immunity were required for maximal Ad5-yCD/mutTKSR39rep-mIL12 activity. The results demonstrate that the addition of IL-12 significantly improves the efficacy of oncolytic adenovirus-mediated suicide gene therapy and provide the scientific basis for future trials targeting locally aggressive cancers.

Citing Articles

Long-Term Follow-Up of Phase I Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin-12 Gene Therapy for Treatment of Metastatic Pancreatic Cancer.

Bhatnagar A, Siddiqui F, Khan G, Pompa R, Kwon D, Nyati S Biomedicines. 2024; 12(5).

PMID: 38791027 PMC: 11118039. DOI: 10.3390/biomedicines12051065.

Evolving Horizons: Adenovirus Vectors' Timeless Influence on Cancer, Gene Therapy and Vaccines.

Trivedi P, Byrne B, Corti M Viruses. 2023; 15(12).

PMID: 38140619 PMC: 10747483. DOI: 10.3390/v15122378.

A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent localized prostate adenocarcinoma.

Nyati S, Stricker H, Barton K, Li P, Elshaikh M, Ali H PLoS One. 2023; 18(9):e0291315.

PMID: 37713401 PMC: 10503775. DOI: 10.1371/journal.pone.0291315.

Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health.

Thoidingjam S, Sriramulu S, Freytag S, Brown S, Kim J, Chetty I Transl Med Commun. 2023; 8(1):11.

PMID: 37065938 PMC: 10088621. DOI: 10.1186/s41231-023-00144-w.

Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter.

Wang G, Liu Y, Liu S, Lin Y, Hu C Int J Mol Sci. 2022; 23(20).

PMID: 36293504 PMC: 9603894. DOI: 10.3390/ijms232012647.

References

Freytag S, Stricker H, Peabody J, Pegg J, Paielli D, Movsas B . Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther. 2007; 15(3):636-42. DOI: 10.1038/sj.mt.6300068. View

Kaufman H, Kim D, DeRaffele G, Mitcham J, Coffin R, Kim-Schulze S . Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2009; 17(3):718-30. DOI: 10.1245/s10434-009-0809-6. View

Del Vecchio M, Bajetta E, Canova S, Lotze M, Wesa A, Parmiani G . Interleukin-12: biological properties and clinical application. Clin Cancer Res. 2007; 13(16):4677-85. DOI: 10.1158/1078-0432.CCR-07-0776. View

Egilmez N, Jong Y, Sabel M, Jacob J, Mathiowitz E, Bankert R . In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 2000; 60(14):3832-7. View

Freytag S, Khil M, Stricker H, Peabody J, Menon M, Deperalta-Venturina M . Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002; 62(17):4968-76. View

Paielli D, Wing M, Rogulski K, Gilbert J, Kolozsvary A, Kim J . Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther. 2000; 1(3):263-74. DOI: 10.1006/mthe.2000.0037. View

Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I . Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther. 2010; 18(10):1874-84. PMC: 2951567. DOI: 10.1038/mt.2010.161. View

Nasu Y, Bangma C, Hull G, Lee H, Hu J, Wang J . Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther. 1999; 6(3):338-49. DOI: 10.1038/sj.gt.3300834. View

Tahara H, Zeh 3rd H, Storkus W, Pappo I, Watkins S, Gubler U . Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 1994; 54(1):182-9. View

10.

Barton K, Stricker H, Elshaikh M, Pegg J, Cheng J, Zhang Y . Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer. Mol Ther. 2011; 19(7):1353-9. PMC: 3129572. DOI: 10.1038/mt.2011.89. View

11.

Kerkar S, Goldszmid R, Muranski P, Chinnasamy D, Yu Z, Reger R . IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest. 2011; 121(12):4746-57. PMC: 3226001. DOI: 10.1172/JCI58814. View

12.

Freytag S, Barton K, Brown S, Narra V, Zhang Y, Tyson D . Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther. 2007; 15(9):1600-6. DOI: 10.1038/sj.mt.6300212. View

13.

Colombo M, Trinchieri G . Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002; 13(2):155-68. DOI: 10.1016/s1359-6101(01)00032-6. View

14.

Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila P, Ugolini M . Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 2010; 70(11):4297-309. DOI: 10.1158/0008-5472.CAN-09-3567. View

15.

Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-46. DOI: 10.1038/nri1001. View

16.

Barton K, Paielli D, Zhang Y, Koul S, Brown S, Lu M . Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther. 2005; 13(2):347-56. DOI: 10.1016/j.ymthe.2005.10.005. View

17.

Barton K, Stricker H, Brown S, Elshaikh M, Aref I, Lu M . Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther. 2008; 16(10):1761-9. PMC: 3127288. DOI: 10.1038/mt.2008.172. View

18.

Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I . Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res. 2013; 19(10):2734-44. DOI: 10.1158/1078-0432.CCR-12-2546. View

19.

Freytag S, Paielli D, Wing M, Rogulski K, Brown S, Kolozsvary A . Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys. 2002; 54(3):873-85. DOI: 10.1016/s0360-3016(02)03005-5. View

20.

Leonard J, Sherman M, Fisher G, Buchanan L, Larsen G, Atkins M . Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997; 90(7):2541-8. View